Transcription factor ZBP-89 in cancer growth and apoptosis

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 36-41

  Zhang, Chris Z Y ^a   Chen, George G ^a   Lai, Paul B S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Cancer; P21waf1; P53; ZBP 89

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; KRUPPEL LIKE FACTOR; OKADAIC ACID; PROTEIN MCL 1; PROTEIN P53; SMALL INTERFERING RNA; STAUROSPORINE; TOPOTECAN; UNCLASSIFIED DRUG; VIMENTIN; ZINC FINGER BINDING PROTEIN 89;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; COLON CANCER; COLORECTAL CANCER; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953692675     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.03.002     Document Type: Review

References (100)

1. Bai L., Yoon S.O., King P.D., Merchant J.L. ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ. 2004, 11:663-673.
2. Bai L., Merchant J.L. ZBP-89 promotes growth arrest through stabilization of p53. Mol. Cell. Biol. 2001, 21:4670-4683.
3. Bai L., Merchant J.L. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J. Biol. Chem. 2000, 275:30725-30733.
4. Bai L., Merchant J.L. ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. Biochem. Biophys. Res. Commun. 2007, 359:817-821.
5. Cheng P.Y., Kagawa N., Takahashi Y., Waterman M.R. Three zinc finger nuclear proteins, Sp1, Sp3, and a ZBP-89 homologue, bind to the cyclic adenosine monophosphate-responsive sequence of the bovine adrenodoxin gene and regulate transcription. Biochemistry 2000, 39:4347-4357.
6. Guyot B., Murai K., Fujiwara Y., Valverde-Garduno V., Hammett M., Wells S., Dear N., Orkin S.H., Porcher C., Vyas P. Characterization of a megakaryocyte-specific enhancer of the key hemopoietic transcription factor GATA1. J. Biol. Chem. 2006, 281:13733-13742.
7. Woo A.J., Moran T.B., Schindler Y.L., Choe S.K., Langer N.B., Sullivan M.R., Fujiwara Y., Paw B.H., Cantor A.B. Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development. Mol. Cell. Biol. 2008, 28:2675-2689.
8. Keates A.C., Keates S., Kwon J.H., Arseneau K.O., Law D.J., Bai L., Merchant J.L., Wang T.C., Kelly C.P. ZBP-89, Sp1, and nuclear factor-kappa B regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 2001, 276:43713-43722.
9. Lantinga-van Leeuwen I.S., Leonhard W.N., Dauwerse H., Baelde H.J., van Oost B.A., Breuning M.H., Peters D.J. Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions. Eur. J. Hum. Genet. 2005, 13:649-659.
10. Fukada T., Tonks N.K. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase. J. Biol. Chem. 2001, 276:25512-25519.
11. Merchant J.L., Iyer G.R., Taylor B.R., Kitchen J.R., Mortensen E.R., Wang Z., Flintoft R.J., Michel J.B., Bassel-Duby R. ZBP-89, a Kruppel-like zinc finger protein, inhibits epidermal growth factor induction of the gastrin promoter. Mol. Cell. Biol. 1996, 16:6644-6653.
12. Law D.J., Tarle S.A., Merchant J.L. The human ZBP-89 homolog, located at chromosome 3q21, represses gastrin gene expression. Mamm. Genome 1998, 9:165-167.
13. Pekarsky Y., Zabarovsky E., Kashuba V., Drabkin H., Sandberg A.A., Morgan R., Rynditch A., Gardiner K. Cloning of breakpoints in 3q21 associated with hematologic malignancy. Cancer Genet. Cytogenet. 1995, 80:1-8.
14. Endoh M., Ogawa M., Orkin S., Nishikawa S. SCL/tal-1-dependent process determines a competence to select the definitive hematopoietic lineage prior to endothelial differentiation. EMBO J. 2002, 21:6700-6708.
15. Kassouf M.T., Chagraoui H., Vyas P., Porcher C. Differential use of SCL/TAL-1 DNA-binding domain in developmental hematopoiesis. Blood 2008, 112:1056-1067.
16. Feo S., Antona V., Cammarata G., Cavaleri F., Passantino R., Rubino P., Giallongo A. Conserved structure and promoter sequence similarity in the mouse and human genes encoding the zinc finger factor BERF-1/BFCOL1/ZBP-89. Biochem. Biophys. Res. Commun. 2001, 283:209-218.
17. Law D.J., Du M., Law G.L., Merchant J.L. ZBP-99 defines a conserved family of transcription factors and regulates ornithine decarboxylase gene expression. Biochem. Biophys. Res. Commun. 1999, 262:113-120.
18. Lisowsky T., Polosa P.L., Sagliano A., Roberti M., Gadaleta M.N., Cantatore P. Identification of human GC-box-binding zinc finger protein, a new Kruppel-like zinc finger protein, by the yeast one-hybrid screening with a GC-rich target sequence. FEBS Lett. 1999, 453:369-374.
19. Law D.J., Labut E.M., Adams R.D., Merchant J.L. An isoform of ZBP-89 predisposes the colon to colitis. Nucleic Acids Res. 2006, 34:1342-1350.
20. Milona M.A., Gough J.E., Edgar A.J. Expression of alternatively spliced isoforms of human Sp7 in osteoblast-like cells. BMC Genomics 2003, 4:43.
21. Salmon M., Zehner Z.E. The transcriptional repressor ZBP-89 and the lack of Sp1/Sp3, c-Jun and Stat3 are important for the down-regulation of the vimentin gene during C2C12 myogenesis. Differentiation 2009, 77:492-504.
22. Zhang X., Diab I.H., Zehner Z.E. ZBP-89 represses vimentin gene transcription by interacting with the transcriptional activator, Sp1. Nucleic Acids Res. 2003, 31:2900-2914.
23. Wu Y., Diab I., Zhang X., Izmailova E.S., Zehner Z.E. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene 2004, 23:168-178.
24. Wu Y., Zhang X., Salmon M., Zehner Z.E. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 2007, 12:905-918.
25. Park H., Shelley C.S., Arnaout M.A. The zinc finger transcription factor ZBP-89 is a repressor of the human beta 2-integrin CD11b gene. Blood 2003, 101:894-902.
26. Bai L., Logsdon C., Merchant J.L. Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer. Int. J. Gastrointest. Cancer 2002, 31:79-88.
27. Ashcroft F.J., Varro A., Dimaline R., Dockray G.J. Control of expression of the lectin-like protein Reg-1 by gastrin: role of the Rho family GTPase RhoA and a C-rich promoter element. Biochem. J. 2004, 381:397-403.
28. Holley-Guthrie E.A., Seaman W.T., Bhende P., Merchant J.L., Kenney S.C. The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J. Virol. 2005, 79:745-755.
29. Law G.L., Itoh H., Law D.J., Mize G.J., Merchant J.L., Morris D.R. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J. Biol. Chem. 1998, 273:19955-19964.
30. Dawson M.I., Park J.H., Chen G., Chao W., Dousman L., Waleh N., Hobbs P.D., Jong L., Toll L., Zhang X., Gu J., Agadir A., Merchant J.L., Bai L., Verma A.K., Thacher S.M., Chandraratna R.A., Shroot B., Hill D.L. Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition. Int. J. Cancer 2001, 91:8-21.
31. Petrovic I., Kovacevic-Grujicic N., Stevanovic M. ZBP-89 and Sp3 down-regulate while NF-Y up-regulates SOX18 promoter activity in HeLa cells. Mol. Biol. Rep. 2009, 36:993-1000.
32. Feng Y., Wang X., Xu L., Pan H., Zhu S., Liang Q., Huang B., Lu J. The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. FEBS J. 2009, 276:4197-4206.
33. Salmon M., Owens G.K., Zehner Z.E. Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program. Biochim. Biophys. Acta 2009, 1793:1144-1155.
34. Hasegawa T., Xiao H., Isobe K. Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter. Biochem. Biophys. Res. Commun. 1999, 256:249-254.
35. Bai L., Kao J.Y., Law D.J., Merchant J.L. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology 2006, 131:841-852.
36. Tvrdik D., Dundr P., Povysil C., Pytlik R., Plankova M. Up-regulation of p21WAF1 expression is mediated by Sp1/Sp3 transcription factors in TGFbeta1-arrested malignant B cells. Med. Sci. Monit. 2006, 12:BR227-BR234.
37. Wang Y., Kobori J.A., Hood L. The ht beta gene encodes a novel CACCC box-binding protein that regulates T-cell receptor gene expression. Mol. Cell. Biol. 1993, 13:5691-5701.
38. Yamada A., Takaki S., Hayashi F., Georgopoulos K., Perlmutter R.M., Takatsu K. Identification and characterization of a transcriptional regulator for the lck proximal promoter. J. Biol. Chem. 2001, 276:18082-18089.
39. Hasegawa T., Takeuchi A., Miyaishi O., Xiao H., Mao J., Isobe K. PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts with the BFCOL1 (binding factor of a type-I collagen promoter) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters. Biochem. J. 2000, 347(Pt 1):55-59.
40. Malo M.S., Mozumder M., Zhang X.B., Biswas S., Chen A., Bai L.C., Merchant J.L., Hodin R.A. Intestinal alkaline phosphatase gene expression is activated by ZBP-89. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G737-G746.
41. Thimmarayappa J., Sun J., Schultz L.E., Dejkhamron P., Lu C., Giallongo A., Merchant J.L., Menon R.K. Inhibition of growth hormone receptor gene expression by saturated fatty acids: role of Kruppel-like zinc finger factor, ZBP-89. Mol. Endocrinol. 2006, 20:2747-2760.
42. Xu Q., Springer L., Merchant J.L., Jiang H. Identification of zinc finger binding protein 89 (ZBP-89) as a transcriptional activator for a major bovine growth hormone receptor promoter. Mol. Cell. Endocrinol. 2006, 251:88-95.
43. Moran A., Iniesta P., de Juan C., Garcia-Aranda C., Diaz-Lopez A., Benito M. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. Cancer Res. 2005, 65:3811-3814.
44. Turner J., Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem. Sci. 1999, 24:236-240.
45. Suske G. The Sp-family of transcription factors. Gene 1999, 238:291-300.
46. Chen G.G., Merchant J.L., Lai P.B., Ho R.L., Hu X., Okada M., Huang S.F., Chui A.K., Law D.J., Li Y.G., Lau W.Y., Li A.K. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am. J. Pathol. 2003, 162:1823-1829.
47. Chen G.G., Chan U.P., Bai L.C., Fung K.Y., Tessier A., To A.K., Merchant J.L., Lai P.B. ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett. 2009, 283:52-58.
48. Schwartz G.K., Shah M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 2005, 23:9408-9421.
49. Albertella M.R., Green C.M., Lehmann A.R., O'Connor M.J. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res. 2005, 65:9799-9806.
50. Serova M., Calvo F., Lokiec F., Koeppel F., Poindessous V., Larsen A.K., Laar E.S., Waters S.J., Cvitkovic E., Raymond E. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother. Pharmacol. 2006, 57:491-499.
51. Traore A., Baudrimont I., Ambaliou S., Dano S.D., Creppy E.E. DNA breaks and cell cycle arrest induced by okadaic acid in Caco-2 cells, a human colonic epithelial cell line. Arch. Toxicol. 2001, 75:110-117.
52. Redkar A., Mixter P., Daoud S.S. Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. J. Exp. Ther. Oncol. 2004, 4:213-222.
53. Ma S., Tang J., Feng J., Xu Y., Yu X., Deng Q., Lu Y. Induction of p21 by p65 in p53 null cells treated with Doxorubicin. Biochim. Biophys. Acta 2008, 1783:935-940.
54. Takeuchi A., Mishina Y., Miyaishi O., Kojima E., Hasegawa T., Isobe K. Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis. Nat. Genet. 2003, 33:172-176.
55. Remington M.C., Tarle S.A., Simon B., Merchant J.L. ZBP-89, a Kruppel-type zinc finger protein, inhibits cell proliferation. Biochem. Biophys. Res. Commun. 1997, 237:230-234.
56. Zhou W., Zhu W.G. The changing face of HDAC inhibitor depsipeptide. Curr. Cancer Drug Targets 2009, 9:91-100.
57. Dagtas A.S., Edens R.E., Gilbert K.M. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. Int. Immunopharmacol. 2009, 9:1289-1297.
58. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp. Cell Res. 1999, 246:280-289.
59. Owen G.I., Richer J.K., Tung L., Takimoto G., Horwitz K.B. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol. Chem. 1998, 273:10696-10701.
60. Merchant J.L., Bai L., Okada M. ZBP-89 mediates butyrate regulation of gene expression. J. Nutr. 2003, 133:2456S-2460S.
61. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., Wu M., Otterson G.A., Zhu W.G. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol. Cell. Biol. 2006, 26:2782-2790.
62. Croxton R., Ma Y., Song L., Haura E.B., Cress W.D. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002, 21:1359-1369.
63. Lin M.T., Juan C.Y., Chang K.J., Chen W.J., Kuo M.L. IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 2001, 22:1947-1953.
64. Komatsu K., Miyashita T., Hang H., Hopkins K.M., Zheng W., Cuddeback S., Yamada M., Lieberman H.B., Wang H.G. Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat. Cell Biol. 2000, 2:1-6.
65. Strasberg Rieber M., Zangemeister-Wittke U., Rieber M. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin. Cancer Res. 2001, 7:1446-1451.
66. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., Fazzalari N.L., Evdokiou A., Atkins G.J. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 2009, 24:1434-1449.
67. Panjala S.R., Thomas S.A., Steinle J.J. Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of dopamine beta hydroxylase (Dbh(-/-)) knockout mice. Auton. Neurosci. 2010, 152:21-26.
68. Amin M.R., Malakooti J., Sandoval R., Dudeja P.K., Ramaswamy K. IFN-gamma and TNF-alpha regulate human NHE3 gene expression by modulating the Sp family transcription factors in human intestinal epithelial cell line C2BBe1. Am. J. Physiol. Cell Physiol. 2006, 291:C887-C896.
69. Bai L., Merchant J.L. Transcription factor ZBP-89 is required for STAT1 constitutive expression. Nucleic Acids Res. 2003, 31:7264-7270.
70. Okada M., Tessier A., Bai L., Merchant J.L. P53 mutants suppress ZBP-89 function. Anticancer Res. 2006, 26:2023-2028.
71. Law D.J., Labut E.M., Merchant J.L. Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia. Mamm. Genome 2006, 17:999-1004.
72. Taniuchi T., Mortensen E.R., Ferguson A., Greenson J., Merchant J.L. Overexpression of ZBP-89, a zinc finger DNA binding protein, in gastric cancer. Biochem. Biophys. Res. Commun. 1997, 233:154-160.
73. Wakabayashi K., Saito H., Kaneko F., Nakamoto N., Tada S., Hibi T. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int. J. Oncol. 2005, 26:233-239.
74. Fukayama M., Hino R., Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008, 99:1726-1733.
75. C. Chao, M.R. Hellmich, Gastrin, inflammation, and carcinogenesis. Curr. Opin. Endocrinol. Diab. Obes. 17 (2010) 33-39.
76. Ohtani N., Zebedee Z., Huot T.J., Stinson J.A., Sugimoto M., Ohashi Y., Sharrocks A.D., Peters G., Hara E. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001, 409:1067-1070.
77. Bandres E., Malumbres R., Cubedo E., Honorato B., Zarate R., Labarga A., Gabisu U., Sola J.J., Garcia-Foncillas J. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol. Rep. 2007, 17:1089-1094.
78. Siavoshian S., Segain J.P., Kornprobst M., Bonnet C., Cherbut C., Galmiche J.P., Blottiere H.M. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 2000, 46:507-514.
79. Borghaei R.C., Gorski G., Javadi M. NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem. Biophys. Res. Commun. 2009, 382:269-273.
80. Juncker-Jensen A., Romer J., Pennington C.J., Lund L.R., Almholt K. Spontaneous metastasis in matrix metalloproteinase 3-deficient mice. Mol. Carcinog. 2009, 48:618-625.
81. C.H. Tang, A. Yamamoto, Y.T. Lin, Y.C. Fong, T.W. Tan, Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochem. Pharmacol. 79 (2010) 209-217.
82. Ehrnstrom R.A., Bjursten L.M., Ljungberg O., Veress B., Haglund M.E., Lindstrom C.G., Andersson T. Dietary supplementation with carbonate increases expression of ornithine decarboxylase and proliferation in gastric mucosa in a rat model of gastric cancer. Int. J. Cancer 2008, 122:727-733.
83. Manni A., Washington S., Mauger D., Hackett D.A., Verderame M.F. Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells. Clin. Exp. Metastasis 2004, 21:461-467.
84. Wei J., Xu G., Wu M., Zhang Y., Li Q., Liu P., Zhu T., Song A., Zhao L., Han Z., Chen G., Wang S., Meng L., Zhou J., Lu Y., Ma D. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008, 28:327-334.
85. Ngan C.Y., Yamamoto H., Seshimo I., Tsujino T., Man-i M., Ikeda J.I., Konishi K., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., Monden M. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br. J. Cancer 2007, 96:986-992.
86. C.A. Elmets, M. Athar, Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans. Cancer Prev. Res. (Phila Pa) 3 (2010) 8-11.
87. Wu K.J., Zeng J., Zhu G.D., Zhang L.L., Zhang D., Li L., Fan J.H., Wang X.Y., He D.L. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol. Sin. 2009, 30:1162-1168.
88. Iwata S., Sato Y., Asada M., Takagi M., Tsujimoto A., Inaba T., Yamada T., Sakamoto S., Yata J., Shimogori T., Igarashi K., Mizutani S. Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene 1999, 18:165-172.
89. Lan Y.T., Chang S.C., Li A.F., Lin T.C., Chen W.S., Jiang J.K., Yang S.H., Wang H.S., Lin J.K. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int. J. Colorectal Dis. 2007, 22:499-506.
90. Yamashita H., Toyama T., Nishio M., Ando Y., Hamaguchi M., Zhang Z., Kobayashi S., Fujii Y., Iwase H. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 2006, 8:R48.
91. Goldberg Z., Levav Y., Krichevsky S., Fibach E., Haupt Y. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004, 3:1188-1195.
92. von Wangenheim K.H., Peterson H.P. The role of cell differentiation in controlling cell multiplication and cancer. J. Cancer Res. Clin. Oncol. 2008, 134:725-741.
93. Britschgi C., Fey M.F. Tumor suppressor genes in myeloid differentiation and leukemogenesis. Future Oncol. 2009, 5:245-257.
94. Fusenig N.E., Breitkreutz D., Boukamp P., Tomakidi P., Stark H.J. Differentiation and tumor progression. Recent Results Cancer Res. 1995, 139:1-19.
95. Botrugno O.A., Santoro F., Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009, 280:134-144.
96. Ohneda K., Ohmori S., Ishijima Y., Nakano M., Yamamoto M. Characterization of a functional ZBP-89 binding site that mediates Gata1 gene expression during hematopoietic development. J. Biol. Chem. 2009, 284:30187-30199.
97. Salmon M., Owens G.K., Zehner Z.E. Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program. Biochim. Biophys. Acta 2009, 7:1144-1155.
98. Boopathi E., Lenka N., Prabu S.K., Fang J.K., Wilkinson F., Atchison M., Giallongo A., Avadhani N.G. Regulation of murine cytochrome c oxidase Vb gene expression during myogenesis: YY-1 and heterogeneous nuclear ribonucleoprotein D-like protein (JKTBP1) reciprocally regulate transcription activity by physical interaction with the BERF-1/ZBP-89 factor. J. Biol. Chem. 2004, 279:35242-35254.
99. Li X., Xiong J.W., Shelley C.S., Park H., Arnaout M.A. The transcription factor ZBP-89 controls generation of the hematopoietic lineage in zebrafish and mouse embryonic stem cells. Development 2006, 133:3641-3650.
100. Wieczorek E., Lin Z., Perkins E.B., Law D.J., Merchant J.L., Zehner Z.E. The zinc finger repressor, ZBP-89, binds to the silencer element of the human vimentin gene and complexes with the transcriptional activator, Sp1. J. Biol. Chem. 2000, 275:12879-12888.